top of page
News, Events and Updates
Search
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
2 days ago
Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
Sep 2
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
Aug 26
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease
Aug 20
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Aug 12
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
Aug 5
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
Jul 31
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
May 14
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
May 13
1
2
3
4
5
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
